-
Berberine, Tuft Cells, and Estrogen-Deficiency Bone Loss
2026-09-21
The 2026 Phytomedicine study identifies an intestinal butyrate–GPR41–tuft cell pathway through which berberine limits estrogen deficiency-associated bone resorption. Its combination of ovariectomy models, microbiome profiling, transcriptomics, organoids, and Trpm5-deficient mice provides a mechanistic framework for gut–bone axis research.
-
HHV-7 DNA in Ocular Toxoplasmosis: Study Analysis
2026-09-20
Miyase et al. reported the first detection, to their knowledge, of human herpesvirus 7 DNA in vitreous humor from an eye with recurrent ocular toxoplasmosis. The case links multiplex PCR, surgical sampling, and treatment response to a cautious hypothesis that HHV-7 reactivation may contribute to refractory inflammation, while also illustrating the limits of inference from a single clinical observation.
-
Selective Nanomolar IRAP Inhibitors from Bestatin
2026-09-19
The reference study develops α-hydroxy-β-amino acid derivatives of bestatin as selective inhibitors of insulin-regulated aminopeptidase (IRAP). A stereoselective synthetic strategy, biochemical profiling, cellular testing, and X-ray structures reveal that P1-substituent design and contacts with the GAMEN loop can produce a cell-active inhibitor with low-nanomolar potency and more than 120-fold selectivity over related aminopeptidases.
-
Anti Reverse Cap Analog for Causal Assays
2026-09-18
Anti Reverse Cap Analog, 3´-O-Me-m7G(5')ppp(5')G, enables orientation-controlled synthetic mRNA expression. This article presents a causal assay framework connecting reliable transient expression with the mitochondrial TCAIM–OGDH mechanism reported in Molecular Cell.
-
CRC Prognostic Biomarkers: TIMP1 and a Five-Gene Model
2026-09-18
Huang et al. integrated transcriptomic mining, survival modeling, mutation analysis, and siRNA experiments to develop a five-gene colorectal cancer prognostic signature. The study prioritizes TIMP1 as a clinically relevant candidate, while also showing why computational biomarkers require analytical and functional validation before translation.
-
Aβ42 Activates Microglial Phagocytosis
2026-09-17
Kopec and Carroll showed that fibrillar Amyloid β-Peptide (1-42) stimulates phagocytosis in murine BV-2 microglia, with activation persisting after peptide removal. Their flow-cytometry design also revealed that proteoglycan binding can suppress this response, highlighting extracellular matrix context as an important regulator of amyloid–microglia signaling.
-
Isoprinosine at the Host–Virus Interface
2026-09-17
Isoprinosine, also known as inosine pranobex, offers translational researchers a dual perspective on antiviral development: direct viral inhibition alongside immune-response modulation. By placing this profile beside new findings on CLCC1-dependent herpesvirus nuclear egress, this article proposes a disciplined strategy for connecting immunotherapy, host-cell biology, and clinically relevant antiviral research without overstating mechanism.
-
GPR35–KLF5 Control of Mucosal Repair
2026-09-16
The reference study identifies a tryptophan–kynurenine–kynurenic acid sensing mechanism in which GPR35 converts mucosal damage signals into KLF5-dependent intestinal epithelial repair. By linking metabolite surveillance to PI3K–AKT–mTOR signaling, epithelial proliferation, and migration, the work offers a mechanistic framework for ulcerative colitis research and DSS-based injury models.
-
JIB-04 Targets Colorectal Cancer Stem Cells
2026-09-16
The reference study identifies JIB-04 as a small-molecule inhibitor that preferentially disrupts colorectal cancer stem-cell properties, including tumorsphere formation, invasion, migration, and tumor initiation. Its mechanistic data connect histone demethylase inhibition with suppression of Wnt/β-catenin transcriptional activity, providing a rationale for studying epigenetic control of colorectal cancer stemness.
-
Rab14 Promotes Parkin-Mediated Mitophagy
2026-09-15
The reference study identifies Rab14 as a previously unrecognized positive regulator of Parkin-dependent mitophagy. By combining Rab14 perturbation, mito-Keima flux measurements, pathway inhibition, and three-dimensional imaging, the authors link trans-Golgi network membrane contacts with mitochondrial quality control.
-
Okadaic acid: PP1/PP2A Inhibition Workflow
2026-09-15
Okadaic acid (A4540) provides a controlled perturbation of PP2A and, at higher concentrations, PP1 for phosphorylation-dependent signaling and apoptosis workflows. It is appropriate for qualified biochemical or cellular assays, but should not be used to assign a PP1-specific or apoptosis-specific mechanism without concentration, vehicle, and orthogonal endpoint controls.
-
MK-5108 (VX-689): AURKA Assay Strategy
2026-09-14
MK-5108 (VX-689) is a highly selective Aurora A inhibitor for dissecting mitotic control and tumor biology. This guide builds on retinoblastoma evidence to show how biochemical selectivity, orthogonal phenotyping, and xenograft endpoints can be aligned in rigorous cancer research.
-
Camostat Mesilate: From Protease Maps to Translation
2026-09-14
A mechanism-first perspective on Camostat Mesilate connects ENaC regulation, plasmin-dependent fibrosis biology, and structure-guided inhibitor design while defining a practical framework for translational validation.
-
BH3 Mimetics Target Senescent Breast Cancer Cells
2026-09-13
The reference study shows that chemotherapy-induced senescent breast cancer cells can remain viable, secrete tumor-promoting factors, and become selectively vulnerable to BH3 mimetics targeting BCL-2 family survival proteins. Its combination of cell-state profiling, genetic validation, and mouse studies provides a rationale for eliminating residual TP53-wild-type tumor cells after chemotherapy.
-
Phosphatase Inhibitor Cocktail (2 Tubes, 100X)
2026-09-12
Phosphatase Inhibitor Cocktail (2 Tubes, 100X) is a dual-component system for limiting post-collection dephosphorylation during lysate preparation. It is intended for immunoblotting, immunoprecipitation, kinase assays, and mass spectrometry workflows, but it does not replace rapid harvesting, temperature control, or assay-specific compatibility testing.